{"entity":{"id":"nct05310643","kind":"trial","name":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","aka":["NIPIRESCUE"],"tldr":"A phase 2 trial of nivolumab and ipilimumab in colorectal cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, now recruiting.","summary":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC is a phase 2, interventional study registered as NCT05310643 by GERCOR - Multidisciplinary Oncology Cooperative Group, with a registry enrolment figure of 30 participants, started 2022-05-05 and due to reach its primary completion in 2025-09. Interventions recorded: Nivolumab; Ipilimumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Objective response rate (ORR) by RECIST 1.1. Colorectal eligibility wording from the registry: \"Histologically confirmed colorectal adenocarcinoma,\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05310643","url":"https://clinicaltrials.gov/study/NCT05310643"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":["gercor"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05310643","phase":"2","setting":"Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy: An Open-label Phase II GERCOR Trial (NIPIRESCUE)","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05310643/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}